Hansen Medical to Exhibit Magellan(TM) Robotic System at Vascular InterVentional Advances Conference MOUNTAIN VIEW, CA -- (Marketwired) -- 10/01/13 -- Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will exhibit its Magellan(TM) Robotic System at the Vascular InterVentional Advances (VIVA) conference, from October 8-11 at the Wynn Hotel in Las Vegas. The Company will be conducting product demonstrations and exhibiting the Magellan Robotic System at Booth 212. "We are excited for the opportunity to further showcase our technology at this important annual meeting of leading clinicians focused on the peripheral vasculature," said Bruce Barclay, President and CEO of Hansen Medical. "Based on the feedback from many successful cases at leading centers across the U.S. and Europe, the precision and control offered by the Magellan Robotic System are helping to bring predictability to a broad variety of endovascular procedures, including endovascular aneurysm repair (EVAR), carotid stenting, peripheral embolization, and chronic total occlusions. In addition, the Magellan System has the potential to allow hospitals and health systems to improve the efficiency and utilization of their most profitable assets -- their operating rooms and cath labs -- by reducing procedure times and streamlining endovascular procedures. With several new robotic catheters in development, we believe the Magellan Robotic System has an important role to play in driving the continued evolution of endovascular treatment options for patients with peripheral vascular disease." About the Magellan(TM) Robotic System Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. Magellan is designed to deliver predictability to simple and complex endovascular procedures. Since its commercial introduction in the US and Europe, the Magellan System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the US and Europe. The system is based upon the flexible robotic technology incorporated in the Sensei-X(R) Rob otic Catheter System currently sold in the U.S. and Europe, which has been used in more than 10,000 patients, but includes a number of key enhancements. In particular, the Magellan Robotic System: -- Provides solid catheter stability for placement of therapeutic devices. -- Is designed to enable predictable procedure times and increased case throughput. -- Allows for independent, individual robotic control of the distal tips of both the outer sheath and the inner leader catheter, as well as robotic manipulation of standard guidewires. -- Is designed to allow for sufficient extension inside the body to access hard to reach peripheral anatomy. -- Preserves the open architecture featured in the Sensei System to allow for the subsequent use of many 6F therapeutic devices on the market today. -- Is designed to potentially reduce physician radiation exposure and fatigue by employing a remote physician workstation. About Hansen Medical, Inc. Hansen Medical, Inc., based in Mountain View, California, is a global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan(TM) Robotic System, 9Fr Magellan(TM) Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei(R) X Robotic Catheter System and Artisan(R) and Artisan Extend(R) Control Catheters are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S., the Company's Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheters are cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the U.S., the Sensei X Robotic Catheter System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com. Forward-Looking Statements This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the potential benefits of our technology and the value of our intellectual property portfolio. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 filed with the SEC on August 9, 2013 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, e ven if new information becomes available. Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries. Investor Contacts: Peter J. Mariani Chief Financial Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting, Inc. Brian Ritchie 212.850.5683 email@example.com John Capodanno 212.850.5705 firstname.lastname@example.org
Hansen Medical to Exhibit Magellan(TM) Robotic System at Vascular InterVentional Advances Conference
Press spacebar to pause and continue. Press esc to stop.